全文获取类型
收费全文 | 17765篇 |
免费 | 1155篇 |
国内免费 | 161篇 |
专业分类
耳鼻咽喉 | 243篇 |
儿科学 | 393篇 |
妇产科学 | 192篇 |
基础医学 | 2166篇 |
口腔科学 | 271篇 |
临床医学 | 1330篇 |
内科学 | 4622篇 |
皮肤病学 | 350篇 |
神经病学 | 1281篇 |
特种医学 | 723篇 |
外科学 | 2575篇 |
综合类 | 215篇 |
一般理论 | 21篇 |
预防医学 | 1140篇 |
眼科学 | 367篇 |
药学 | 1141篇 |
中国医学 | 62篇 |
肿瘤学 | 1989篇 |
出版年
2023年 | 101篇 |
2022年 | 160篇 |
2021年 | 394篇 |
2020年 | 278篇 |
2019年 | 366篇 |
2018年 | 403篇 |
2017年 | 405篇 |
2016年 | 449篇 |
2015年 | 494篇 |
2014年 | 614篇 |
2013年 | 750篇 |
2012年 | 1235篇 |
2011年 | 1214篇 |
2010年 | 737篇 |
2009年 | 609篇 |
2008年 | 1134篇 |
2007年 | 1228篇 |
2006年 | 1109篇 |
2005年 | 1149篇 |
2004年 | 1016篇 |
2003年 | 1079篇 |
2002年 | 1022篇 |
2001年 | 281篇 |
2000年 | 250篇 |
1999年 | 269篇 |
1998年 | 192篇 |
1997年 | 215篇 |
1996年 | 165篇 |
1995年 | 156篇 |
1994年 | 111篇 |
1993年 | 99篇 |
1992年 | 133篇 |
1991年 | 100篇 |
1990年 | 117篇 |
1989年 | 111篇 |
1988年 | 110篇 |
1987年 | 84篇 |
1986年 | 71篇 |
1985年 | 73篇 |
1984年 | 54篇 |
1983年 | 70篇 |
1982年 | 32篇 |
1981年 | 38篇 |
1980年 | 32篇 |
1979年 | 38篇 |
1978年 | 31篇 |
1977年 | 37篇 |
1976年 | 22篇 |
1974年 | 26篇 |
1972年 | 23篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
Ken Yamaguchi Katsumi Aoyagi Ken-ichi Urakami Toyoharu Fukutani Noboru Maki Shigehiro Yamamoto Kotomi Otsubo Yoshio Miyake Tetsuro Kodama 《Cancer science》1995,86(7):698-705
Our previous study demonstrated that pro-gastrin-releasing peptide(31–98), or ProGRP, is a specific tumor marker in patients with small cell lung carcinoma (SCLC). Using a newly developed, highly sensitive enzyme-linked immunosorbent assay (ELISA) for ProGRP, we analyzed 1,446 samples including those obtained from 478 lung cancer patients to evaluate the clinical usefulness of this ELISA. Several properties indicated that ProGRP is a useful tumor marker for SCLC. First, ProGRP was specifically elevated in SCLC patients. In non-SCLC patients and patients with non-tumorous lung diseases, its serum level was very rarely elevated. Secondly, ProGRP was a reliable marker, in terms of the marked elevation of serum ProGRP levels in SCLC patients. Thirdly, serum ProGRP levels were elevated in SCLC patients even at a relatively early stage of this disease. Fourthly, changes in the serum ProGRP level showed an excellent correlation with the therapeutic responses in SCLC patients. Neuron-specific enolase (NSE) is accepted as a tumor marker of SCLC patients. With the aim of comparing ProGRP and NSE as tumor markers for SCLC patients, we measured serum NSE levels in all samples collected in the present study. We found that ProGRP was superior to NSE in terms of sensitivity, specificity and reliability. Therefore, we consider that ProGRP can play a major role as a clinical tumor marker for SCLC patients. 相似文献
72.
Summary: A 6.5-year-old boy developed seizures at age 2.8 years consisting of episodes of unconsciousness and laughing attacks. By age 6 years, multiple seizure types, including generalized tonic-clonic (GTC), complex partial (CPS) and akinetic seizures, and drop attacks were occurring several times daily. EEG showed multifocal epileptic discharges. Antiepileptic drugs (AEDs) did not control the seizures. With progression of the epilepsy, cognitive deterioration developed. There were no manifestations of precocious puberty. Neuroimaging disclosed a suprasellar mass in continuity with the hypothalamus, and a diagnosis of hypothalamic hamartoma was made. After surgical resection of the hamartoma, the seizures were completely alleviated, and the epileptic EEG discharges disappeared. Improvement of mental function was also noted. 相似文献
73.
Masaaki Kataoka Masashi Kawamura Takaharu Tsuda Hisao Itoh Akira Komatsu Shuji Tanada Atsushi lio Ken Hamamoto 《European journal of nuclear medicine and molecular imaging》1990,17(3-4):142-147
To evaluate the clinical usefulness of gallium 67 imaging in the detection of gastrointestinal (GI) non-Hodgkin's lymphoma (NHL) and in the assessment of the therapeutic effects, images were reviewed in 24 cases (25 lesions: stomach, 20; ileum, 2; and terminal ileum and/or cecum, 3) and were compared using barium studies and, in 16 cases, computerized tomography (CT). In all, 23 (92.0%) of the 25 lesions were detected by67Ga citrate imaging, the barium studies detected all 25, and CT detected 15 of 16 lesions (93.8%). The two lesions not identified by imaging and the one not found by CT were the smallest of all. In 2 (8.7%) of the 23 lesions positively identified by67Ga-citrate imaging, both CT and imaging revealed the extent of the tumor more accurately than did the barium studies. In all but one of the patients, a close correlation existed between the imaging results and the therapeutic effects. These data suggest that67Ga imaging is useful in conjunction with CT and barium studies for the detection of GI NHL and for the assessment of both the spatial extent of disease and the therapeutic effects, although a lack of67Ga uptake after therapy does not always indicate a good therapeutic effect. 相似文献
74.
75.
76.
O Yoshida Y Kakehi Y Nishio T Tomoyoshi T Konami T Usui M Igawa I Takenaka K Fujita 《Hinyokika kiyo. Acta urologica Japonica》1992,38(12):1437-1443
The influence of N1-(2-tetrahydrofuryl)-5-fluorouracil plus uracil (UFT) on the recurrence of superficial bladder tumors was evaluated in a randomized clinical study. Group A (n = 196) underwent transurethral resection (TUR) and the intravesical chemoprophylaxis, while group B (n = 193) received 400 mg per a day of UFT orally for 6 months in addition to the instillation therapy. These adjuvant therapy was started one week after TUR. Consequently, 30 patients in group B showed UFT-related toxicity and administration of UFT was discontinued in 10 of them. In addition, 87 patients in group B did not complete the 6-month course of UFT administration. Comparison of 2-year actuarial non-recurrence curves revealed no significant difference between groups A and B. However, UFT seemed to have a favorable prophylactic effect when recurrence rates were compared among those patients with recurrent tumors (generalized Wilcoxon: p = 0.1277), and those with recurrent multiple tumors (p = 0.0847). 相似文献
77.
Kentaro Kunimori Kiyoshi Harada Yutaka Maruoka Ken Omura 《Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics》2006,101(2):e23-e27
Trichorhinophalangeal syndrome (TRPS) type I is characterized by slowly progressing systemic osseous dysplasia, exhibiting craniofacial and other skeletal deformities. However, there have been few reports describing this syndrome after undergoing orthognathic surgery. In this report, we present a patient with TRPS I who successfully underwent orthognathic surgery. In addition, we examined the skeletal stability of the patient for 2 years after the surgery. 相似文献
78.
Clinical characteristics of thrombotic microangiopathy following ABO incompatible living donor liver transplantation. 总被引:1,自引:0,他引:1
Ryohei Miyata Motohide Shimazu Minoru Tanabe Shigeyuki Kawachi Ken Hoshino Go Wakabayashi Yoko Kawai Masaki Kitajima 《Liver transplantation》2007,13(10):1455-1462
Thrombotic microangiopathy (TMA) may develop after living donor liver transplantation (LDLT), but the mechanism is not fully understood. We retrospectively analyzed all patients undergoing LDLT at our center, including TMA patients, to elucidate the clinical characteristics and presentation and to determine which patients have a higher risk of occurrence of TMA. In all, 57 adult patients were reviewed after LDLT at our institution. TMA was diagnosed by sudden and severe thrombocytopenia, followed by hemolytic anemia with fractionated erythrocytes in the blood smear. Clinical features were compared between the TMA group and the non-TMA group. Of the 57 patients, 4 were diagnosed with posttransplantation TMA. ABO blood group (ABO)-incompatibility, cyclophosphamide (CPA), and recipient blood group (type O) were closely correlated with the occurrence of TMA. Thrombocytopenia appeared 1 to 5 days before hemolytic anemia. Coagulative function markers stayed at the same level after TMA, while marked elevation was shown in fibrinolytic function markers such as plasminogen activator inhibitor type 1 (PAI-1). TMA occurred at a higher prevalence in ABO-incompatible graft recipients. Additional factors associated with ABO-incompatible transplantation, such as an overdose of immunosuppressants, may affect the likelihood of TMA. Sudden and severe thrombocytopenia presented before hemolytic anemia and the serum levels of PAI-1 correlated well with the clinical course of TMA. In conclusion, early recognition of thrombocytopenia and elevation of PAI-1 is crucial to diagnose TMA especially in ABO-incompatible LDLT. 相似文献
79.
Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. 总被引:2,自引:0,他引:2
Naoya Kakimoto Takehiro Inoue Toshihiko Inoue Shumei Murakami Souhei Furukawa Ken Yoshida Yasuo Yoshioka Hideya Yamazaki Eiichi Tanaka Kimishige Shimizutani 《Radiotherapy and oncology》2003,68(2):123-128
PURPOSE: To evaluate the treatment results of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (ISBT) for T3 mobile tongue cancer. MATERIAL AND METHODS: Between 1974 and 1992, 61 patients with T3 mobile tongue cancer were treated with LDR ISBT using (192)Ir hairpins with or without single pins. In addition, between 1991 and 1999, 14 patients were treated with HDR ISBT. For nine patients treated with ISBT alone, the total dose was 59-94 Gy (median 72 Gy) within one week in LDR ISBT and 60 Gy/10 fractions/5 days in HDR ISBT. For 66 patients treated with a combination therapy of external beam radiotherapy (EBRT) and ISBT, the total dose was 12.5-60 Gy (median 30 Gy) of EBRT and 50-112 Gy (median 68 Gy) within 1 week in LDR ISBT or 32-60 Gy (median 48 Gy)/8-10 fractions/5-7 days in HDR ISBT. RESULTS: The 2- and 3-year local control rates of all patients were both 68%. The 2- and 3-year local control rates of patients treated with LDR ISBT were both 67%, and those with HDR ISBT were both 71%. The local control rate of patients treated with HDR ISBT was similar to those with LDR ISBT. CONCLUSIONS: ISBT for T3 mobile tongue cancer is effective and acceptable. The treatment result of HDR ISBT is almost similar to that of LDR ISBT for T3 mobile tongue cancer. 相似文献
80.